Samenvatting: Incyte maakt langetermijngegevens van 24 weken bekend uit de Fase 3 TRuE-AD4-studie van Opzelura® (ruxolitinib) crème bij volwassenen met matige atopische dermatitis

Key Takeaway: Incyte has released long-term data from the 24-week Phase 3 TRuE-AD4 study of Opzelura® (ruxolitinib) cream for adults with moderate atopic dermatitis. The study's findings are significant for understanding the treatment's efficacy and safety profile. Further details on the results were not provided in the article.